Elanco Animal Health Incorporated (NYSE:ELAN) Director Acquires $102,000.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius purchased 10,000 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Friday, March 7th, Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock. The stock was bought at an average price of $10.90 per share, for a total transaction of $109,000.00.

Elanco Animal Health Trading Up 3.5 %

ELAN stock opened at $10.40 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company’s 50-day simple moving average is $11.52 and its 200 day simple moving average is $12.81. Elanco Animal Health Incorporated has a 52 week low of $10.03 and a 52 week high of $18.80. The company has a market capitalization of $5.14 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue was down 1.4% on a year-over-year basis. During the same quarter last year, the company posted $0.08 earnings per share. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELAN has been the topic of several research reports. Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Piper Sandler decreased their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Stifel Nicolaus decreased their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, UBS Group decreased their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $15.17.

Institutional Investors Weigh In On Elanco Animal Health

A number of large investors have recently bought and sold shares of ELAN. CoreCap Advisors LLC acquired a new stake in Elanco Animal Health during the fourth quarter worth about $29,000. AM Squared Ltd acquired a new stake in Elanco Animal Health during the third quarter worth about $34,000. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health during the third quarter worth about $35,000. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after buying an additional 2,044 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after buying an additional 1,601 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.